...Rating pressure would stem from a rise in leverage above 1.8x in the intermediate term. The increase in total debt leverage would likely result from oprational stress and/or incremental borrowing to fund acquisitions or share repurchases. Fitch does not anticipate a positive rating action in the near term. However, the Outlook could be revised to Stable if Merck pursues a more conservative capital deployment strategy with leverage below 1.5x....